Midatech’s FY results are broadly in line with expectations, following the trading update in January. The acquisition of NASDAQ-listed DARA Biosciences in Dec 2015, which brought a US sales team and a portfolio of mainly oncology support products, is expected to drive significant revenue growth in the years ahead; Phase II results for MidaForm™- Insulin-PharmFilm™ remain expected in Q2 2016; and IND enabling studies for the company’s brain cancer and liver cancer programmes are expected to comme ....
13 Apr 2016
FY results in line; Phase II insulin data remains expected in Q2
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY results in line; Phase II insulin data remains expected in Q2
- Published:
13 Apr 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
Midatech’s FY results are broadly in line with expectations, following the trading update in January. The acquisition of NASDAQ-listed DARA Biosciences in Dec 2015, which brought a US sales team and a portfolio of mainly oncology support products, is expected to drive significant revenue growth in the years ahead; Phase II results for MidaForm™- Insulin-PharmFilm™ remain expected in Q2 2016; and IND enabling studies for the company’s brain cancer and liver cancer programmes are expected to comme ....